RareStone Group

Rarestone group email format

Verified email-pattern data for Rarestone Group is currently limited. You can still use the company insights and contact sections below.
RareStone Group is committed to establishing Greater China's first integrated rare disease ecosystem, transforming the lives of patients and families through world-class therapeutics and comprehensive, sustainable support services. We have two subsidiaries under RareStone Group: Citrine Medicine is a specialty pharmaceutical company dedicated to delivering innovative, accessible treatments for rare diseases in Greater China, with a focus on neurology. WAKIX® is our core product, which has been approved by China NMPA in 2023 for narcolepsy, and it has been listed in the National Reimbursement Drug List in 2023. WAKIX® has obtained pediatric narcolepsy indication from China NMPA in May 2024. Zircon Health is a pioneering healthcare services platform building China's first rare disease ecosystem through: - AI-powered, patient-centric disease management solutions - Digital health technologies and big data analytics - Comprehensive non-therapeutic support services - Innovative payment models to enhance treatment accessibility In July 2020, RareStone Group secured $80 million USD in Series A funding from leading investors including Eight Roads Ventures, F-Prime Capital, and Vivo Capital.
Looking for a particular RareStone Group employee's phone or email?

Rarestone Group Questions

Explore related pages

Related company profiles:

Top RareStone Group Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant